Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s617, 2025. DOI: 10.25251/gf6mb511. Disponível em: https://skin.dermsquared.com/skin/article/view/3821. Acesso em: 29 apr. 2026.